Obiltoxaximab
Products Obiltoxaximab was approved in the United States in 2016 as an infusion product (Anthim). It has not yet been registered in many countries. Obiltoxaximab was developed with funding from national organizations and is intended primarily for the treatment of victims of a terrorist attack with anthrax spores (Strategic National Stockpile). Structure and properties Obiltoxaximab … Obiltoxaximab
